Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) have earned an average recommendation of “Buy” from the twenty-one ratings firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and thirteen have issued a buy recommendation on the company. The average 1-year target price among brokers that have covered the stock in the last year is $182.00.

A number of brokerages have issued reports on JAZZ. Barclays set a $164.00 price objective on Jazz Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, July 3rd. Cantor Fitzgerald reissued a “buy” rating and set a $185.00 price objective on shares of Jazz Pharmaceuticals in a report on Tuesday, March 26th. Wells Fargo & Co reissued a “hold” rating and set a $68.00 price objective (up from $65.00) on shares of Colgate-Palmolive in a report on Monday, June 17th. BMO Capital Markets set a $208.00 price objective on Jazz Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, July 3rd. Finally, Piper Jaffray Companies set a $202.00 price target on Jazz Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, May 28th.

Shares of NASDAQ JAZZ traded down $1.61 during midday trading on Friday, reaching $136.62. 537,646 shares of the company traded hands, compared to its average volume of 444,876. The firm has a market capitalization of $7.74 billion, a price-to-earnings ratio of 11.16, a PEG ratio of 1.14 and a beta of 1.15. The business’s 50-day moving average price is $134.77. Jazz Pharmaceuticals has a 12 month low of $113.52 and a 12 month high of $181.46. The company has a current ratio of 3.15, a quick ratio of 3.01 and a debt-to-equity ratio of 0.63.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, May 7th. The specialty pharmaceutical company reported $3.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.83 by $0.44. The company had revenue of $508.19 million during the quarter, compared to analysts’ expectations of $466.55 million. Jazz Pharmaceuticals had a return on equity of 27.35% and a net margin of 24.88%. The business’s revenue was up 14.3% on a year-over-year basis. During the same period last year, the business earned $2.98 earnings per share. Equities analysts expect that Jazz Pharmaceuticals will post 13.23 earnings per share for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the stock. Amundi Pioneer Asset Management Inc. raised its holdings in Jazz Pharmaceuticals by 65.9% during the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 371,182 shares of the specialty pharmaceutical company’s stock worth $46,011,000 after purchasing an additional 147,419 shares during the last quarter. Millennium Management LLC raised its holdings in Jazz Pharmaceuticals by 120.6% during the 4th quarter. Millennium Management LLC now owns 252,406 shares of the specialty pharmaceutical company’s stock worth $31,288,000 after purchasing an additional 138,007 shares during the last quarter. State Board of Administration of Florida Retirement System raised its holdings in Jazz Pharmaceuticals by 4.2% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 73,439 shares of the specialty pharmaceutical company’s stock worth $10,498,000 after purchasing an additional 2,974 shares during the last quarter. Envestnet Asset Management Inc. raised its holdings in Jazz Pharmaceuticals by 16.8% during the 1st quarter. Envestnet Asset Management Inc. now owns 45,261 shares of the specialty pharmaceutical company’s stock worth $6,470,000 after purchasing an additional 6,496 shares during the last quarter. Finally, California State Teachers Retirement System raised its holdings in Jazz Pharmaceuticals by 2.0% during the 4th quarter. California State Teachers Retirement System now owns 93,782 shares of the specialty pharmaceutical company’s stock worth $11,625,000 after purchasing an additional 1,810 shares during the last quarter. 89.81% of the stock is owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Recommended Story: How to start trading in the forex market?

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.